T 0488/16 (Dasatinib/BRISTOL-MYERS SQUIB) of 01.02.2017

European Case Law Identifier: ECLI:EP:BA:2017:T048816.20170201
Date of decision: 1 February 2017
Case number: T 0488/16
Petition for review of: -
Application number: 00922102.9
IPC class: C07D 213/81 A61K 31/426 C07D 213/82 C07D 239/42 C07D 417/12 C07D 233/90 C07D 409/12 C07C 237/40 C07D 277/56 C07D 231/38 C07D 263/48
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: CYCLIC PROTEIN TYROSINE KINASE INHIBITORS
Applicant name: Bristol-Myers Squibb Holdings Ireland
Opponent name: Isenbruck Bösl Hörschler LLP
APOTEX INC.
Actavis Group PTC ehf
Generics [UK] Limited
Board: 3.3.01
Headnote: -
Relevant legal provisions: European Patent Convention Art 112(1)(a)European Patent Convention Art 56
Keywords: Inventive step - (no)
No plausible solution of the technical problem
Solution to less ambitiously defined problem obvious
Referral to the Enlarged Board of Appeal - (no)
Catchword: -
Cited cases: T 0022/82 T 0939/92 T 0320/01 T 0715/03 T 0604/04 T 1329/04 T 1336/04 T 0433/05 T 0578/06 T 0536/07 T 1642/07 T 0716/08 T 0108/09 T 1043/10 T 0210/11 T 1677/11 T 0428/12 T 0863/12
Citing cases: G 0002/21 T 0227/14 T 0184/16 T 0500/16 T 1099/16 T 2320/16 T 2730/16 T 1322/17 T 2593/17 T 2627/17 T 0116/18 T 0689/19 T 2015/20

Order

For these reasons it is decided that:

1. The appeal is dismissed.

2. The request for referral to the Enlarged Board of Appeal is rejected.